Related Experiment Video
Updated: Jun 22, 2025
Three-Dimensional 3D Tumor Spheroid Invasion Assay
Published on: May 1, 2015
The Role of αvβ3 Integrin in Cancer Therapy Resistance
Bianca Cruz Pachane1,2, Heloisa S Selistre-de-Araujo1
1Biochemistry and Molecular Biology Laboratory, Department of Physiological Sciences, Universidade Federal de São Carlos (UFSCar), São Carlos 13565-905, SP, Brazil.
Abstract:
A relevant challenge for the treatment of patients with neoplasia is the development of resistance to chemo-, immune-, and radiotherapies. Although the causes of therapy resistance are poorly understood, evidence suggests it relies on compensatory mechanisms that cells develop to replace specific intracellular signaling that should be inactive after pharmacological inhibition. One such mechanism involves integrins, membrane receptors that connect cells to the extracellular matrix and have a crucial role in cell migration. The blockage of one specific type of integrin is frequently compensated by the overexpression of another integrin dimer, generally supporting cell adhesion and migration. In particular, integrin αvβ3 is a key receptor involved in tumor resistance to treatments with tyrosine kinase inhibitors, immune checkpoint inhibitors, and radiotherapy; however, the specific inhibition of the αvβ3 integrin is not enough to avoid tumor relapse. Here, we review the role of integrin αvβ3 in tumor resistance to therapy and the mechanisms that have been proposed thus far. Despite our focus on the αvβ3 integrin, it is important to note that other integrins have also been implicated in drug resistance and that the collaborative action between these receptors should not be neglected.
Insights
Therapy resistance in cancer is a major challenge. Integrins, like alpha-v-beta-3 (αvβ3), play a key role in this resistance, often through compensatory mechanisms that promote tumor cell survival and migration.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Cancer therapy resistance (chemo-, immune-, radiotherapy) is a significant clinical challenge.
- Therapy resistance is often driven by cellular compensatory mechanisms that bypass inhibited signaling pathways.
- Integrins, crucial for cell-extracellular matrix interactions and migration, are implicated in these resistance mechanisms.
Purpose of the Study:
- To review the role of integrin αvβ3 in tumor resistance to various cancer therapies.
- To explore proposed mechanisms by which integrin αvβ3 contributes to treatment failure.
- To highlight the importance of integrin αvβ3 in overcoming therapeutic resistance.
Main Methods:
- Literature review focusing on integrin αvβ3 and cancer therapy resistance.
- Analysis of studies investigating compensatory signaling pathways in cancer cells.
- Examination of research on integrin overexpression and its link to treatment outcomes.
Main Results:
- Integrin αvβ3 is a key receptor involved in resistance to tyrosine kinase inhibitors, immune checkpoint inhibitors, and radiotherapy.
- Inhibition of one integrin type can lead to compensatory overexpression of others, promoting cell adhesion and migration.
- Specific inhibition of αvβ3 alone is insufficient to prevent tumor relapse, suggesting complex integrin interactions.
Conclusions:
- Integrin αvβ3 plays a critical role in mediating tumor resistance to multiple cancer therapies.
- Understanding integrin-mediated compensatory mechanisms is essential for developing effective cancer treatments.
- The collaborative action of multiple integrins in drug resistance warrants further investigation.
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
Some...
01:15Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
01:10Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
02:56Treatment Resistant Cancers
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...